News Channels

10 Dec 2019 UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
09 Dec 2019 Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I
09 Dec 2019 FORMA Therapeutics Announces Clinical Data for Sickle Cell Disease Candidate FT-4202, Demonstrating Multi-modal Activity of PKR Activation Increases Oxygen Affinity and Decreases Sickle Hemoglobin Polymerization, at 61st Annual ASH Meeting
09 Dec 2019 FORMA Therapeutics Announces Positive Preliminary Phase 1/2 IDH1m Inhibitor Olutasidenib Results Demonstrating Rapid Clinical Remissions and Mutation Clearance in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
09 Dec 2019 Seven and Eight BioPharmaceuticals, Inc. Announces Clinical Collaboration to Evaluate BDB001 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
09 Dec 2019 Celularity Presents Pre-Clinical and Clinical Data from its Allogeneic, Placental-Derived, Off-the-Shelf Cell Therapy Platform at the 2019 ASH Annual Meeting
09 Dec 2019 Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting
09 Dec 2019 Samyang Biopharm USA, Inc. and Talix Therapeutics NV Announce Global Strategic Collaboration to Advance Novel Immuno-Oncology Therapeutic
09 Dec 2019 Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug Conjugate
09 Dec 2019 Alpine Immune Sciences Presents ALPN-101 Phase 1 Healthy Volunteer Study Data and Details of Upcoming Phase I/II BALANCE GVHD Study at the 61st American Society of Hematology Annual Meeting
09 Dec 2019 IONTAS Antibody Enters Clinical Trial for Use in the Treatment of B Cell Acute Lymphoblastic Leukemia
09 Dec 2019 Sesen Bio Initiates Rolling Submission of BLA for Vicinium to FDA
09 Dec 2019 Sangamo Announces Preliminary Results From the First Three Patients in a Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-edited Cell Therapy in Beta Thalassemia
09 Dec 2019 Merck to Acquire ArQule, Advancing Leadership in Oncology
09 Dec 2019 Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy
09 Dec 2019 Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs
09 Dec 2019 Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
09 Dec 2019 Autolus Therapeutics Announces New Data Showcasing Clinical Progress of AUTO3 in B Cell Malignancies
09 Dec 2019 Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion
09 Dec 2019 ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up